I’ve talked about this promising research before…
Statins are being studied as a treatment for sarcopenia (age-related muscle loss).
There is emerging evidence that they protect our muscles as we get older.
The mechanisms are hormetic.
A recent review article summarizes the evidence to date:
Paper · Front. Pharmacol. · 2025Effects of statins on sarcopenia with focus on mechanistic insights and future perspectivesSarcopenia is an age-related geriatric syndrome characterized by the progressive decline in skeletal muscle mass and function. Its pathogenesis is multifactorial, involving complex interactions between inflammatory responses, oxidative stress, and mitochondrial dysfunction. In recent years, statins, widely used as lipid-lowering agents, have garnered attention for their pleiotropic biological effects, particularly…frontiersin.orgQuoted:
“Sarcopenia is an age-related geriatric syndrome characterized by the progressive decline in skeletal muscle mass and function. Its pathogenesis is multifactorial, involving complex interactions between inflammatory responses, oxidative stress, and mitochondrial dysfunction. In recent years, statins, widely used as lipid-lowering agents, have garnered attention for their pleiotropic biological effects, particularly in their potential therapeutic value for anti-inflammatory, antioxidant, microcirculation improvement, and regulation of skeletal muscle metabolism. Statins have demonstrated promising potential in the prevention and treatment of sarcopenia. This review systematically examines the mechanisms through which statins act in sarcopenia, highlighting their pharmacological properties, biological effects, and relevant clinical and preclinical research advancements. Existing studies suggest that moderate statin use may improve the skeletal muscle microenvironment and maintain mitochondrial homeostasis by inhibiting the NF-κB signaling pathway, activating the Nrf2/ARE pathway, and modulating the AMPK/SIRT1/PGC-1α pathways.”
Also see these previous posts:
↪ Statin muscle toxicity overstated: rhabdomyolysis ~1 in 100,000; sarcopenia use studied
↪ Statins activate AMPK, the same longevity pathway as metformin
↪ Statins create mild mitochondrial stress that triggers protective mitohormesis
#statinsHD #statinsmuscleHD #sarcopeniaHD #muscleHD #hormesisHD

